Wilgenhof et al. described a phase IB trial that enrolled 15 advanced melanoma patients who were subjected to vaccination with autologous monocyte-derived DCs electroporated with synthetic mRNA (TriMixDC-MEL).149 The report revealed that the mRNA encoded CD40L, TLR4, CD70, HLA-II targeting signal, and a TAA (MAGE-A3, MAGE-C2, tyrosinase, or gp100). The gene discussed is CD70; the disease is melanoma.